https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-12-01 / Br. J. Haematol. 1999 Dec;107(3):648-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-12-01 / Br. J. Haematol. 1999 Dec;107(3):648-551999-12-01 00:00:002019-02-15 08:51:16Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-07-02 / Int. J. Cancer 1999 Jul;82(1):121-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-07-02 / Int. J. Cancer 1999 Jul;82(1):121-41999-07-02 00:00:002019-02-15 08:39:05Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-81999-06-01 00:00:002019-02-15 08:39:12A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-03-01 / J. Urol. 1999 Mar;161(3):777-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-03-01 / J. Urol. 1999 Mar;161(3):777-821999-03-01 00:00:002019-02-15 08:48:12Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-01-01 / Urol Int 1999;63(3):151-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-01-01 / Urol Int 1999;63(3):151-91999-01-01 00:00:001999-01-01 00:00:00Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-06-01 / J Surg Oncol 1998 Jun;68(2):79-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-06-01 / J Surg Oncol 1998 Jun;68(2):79-911998-06-01 00:00:002019-02-15 08:53:20Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1998-04-01 / Nat. Biotechnol. 1998 Apr;16(4):364-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1998-04-01 / Nat. Biotechnol. 1998 Apr;16(4):364-91998-04-01 00:00:002019-02-15 08:39:04Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1997-09-01 / Prostate 1997 Sep;32(4):272-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1997-09-01 / Prostate 1997 Sep;32(4):272-81997-09-01 00:00:002019-02-15 08:53:04Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1997-03-17 / Int. J. Cancer 1997 Mar;70(6):706-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1997-03-17 / Int. J. Cancer 1997 Mar;70(6):706-151997-03-17 00:00:002019-02-15 08:53:40Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1996-12-01 / Prostate 1996 Dec;29(6):371-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1996-12-01 / Prostate 1996 Dec;29(6):371-801996-12-01 00:00:002019-02-15 08:53:05Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
